Chris Dickhoff
Overview
Explore the profile of Chris Dickhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Jonge W, Smits B, Ket J, Altenburg J, Annema J, Daniels J, et al.
ERJ Open Res
. 2025 Mar;
11(2).
PMID: 40040906
Aims: Parapneumonic pleural infections are frequently encountered, but the optimal treatment regimen remains controversial. The aim of this systematic review was to investigate whether immediate video-assisted thoracoscopic surgery (VATS) has...
2.
Houda I, Bahce I, Dickhoff C, Kroese T, Kroeze S, Mariolo A, et al.
Lung Cancer
. 2024 Dec;
199:108061.
PMID: 39705827
Introduction: The EORTC-Lung Cancer Group initiated a Delphi consensus process to establish a consensual definition of resectable stage III non-small cell lung cancer (NSCLC) for the use in clinical trials,...
3.
Celli L, Garrelfs M, Sakkers R, Elting M, Celli M, Bokenkamp A, et al.
Calcif Tissue Int
. 2024 Nov;
115(6):960-975.
PMID: 39535563
Osteogenesis Imperfecta (OI), known as "brittle bone disease," presents a rare genetic disorder characterized by bone fragility, often accompanied by skeletal deformities and extraskeletal complications. OI is primarily associated with...
4.
Filipello F, Blaauwgeers H, Lissenberg-Witte B, Schonau A, Doglioni C, Arrigoni G, et al.
Lung Cancer
. 2024 Oct;
197:107987.
PMID: 39388963
Recognizing non-invasive growth patterns is necessary for correct diagnosis, invasive size determination and pT-stage in resected non-small cell lung carcinoma. Due to iatrogenic collapse after resection, the distinction between adenocarcinoma...
5.
Wijngaarden J, Slebe M, Pouw J, Oprea-Lager D, Schuit R, Dickhoff C, et al.
Eur J Nucl Med Mol Imaging
. 2024 Oct;
52(2):719-729.
PMID: 39377810
Introduction: The novel positron emission tomography (PET) imaging tracer, [F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was...
6.
Bahce I, Dickhoff C, Schneiders F, Veltman J, Heineman D, Hashemi S, et al.
J Immunother Cancer
. 2024 Sep;
12(9).
PMID: 39349061
Background: In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable,...
7.
Smesseim I, Morin-Thibault L, Herth F, Tonkin J, Shah P, Slebos D, et al.
Respiration
. 2024 Jun;
103(9):544-562.
PMID: 38870914
Introduction: Persistent air leak (PAL) is associated with prolonged hospitalization, high morbidity and increased treatment costs. Conservative treatment consists of observation, chest tube drainage, and pleurodesis. Guidelines recommend surgical evaluation...
8.
Dickhoff C, Heineman D, van Dorp M, Senan S, Bahce I
J Thorac Oncol
. 2024 Jun;
19(6):862-865.
PMID: 38849166
No abstract available.
9.
Blaauwgeers H, Dickhoff C, Pelosi G, Timens W, Filipello F, Minami Y, et al.
J Thorac Oncol
. 2024 May;
19(5):671-676.
PMID: 38719423
No abstract available.
10.
Kalverda K, Ninaber M, Wijmans L, Von Der Thusen J, Jonkers R, Daniels J, et al.
Lancet Respir Med
. 2024 Apr;
12(7):513-522.
PMID: 38640934
Background: An adequate diagnosis for interstitial lung disease (ILD) is important for clinical decision making and prognosis. In most patients with ILD, an accurate diagnosis can be made by clinical...